Doxorubicin — Drug Intelligence | 43 EU Trials

Filter these 43 trials by condition, phase, country and more.

Open in Search →

43 Registered trials

17 Recruiting

24 Completed trials

28 Sponsors

24 Countries

Phase III

Phase II

Phase III: 23 Phase II/III: 3 Phase II: 13 Phase I/II: 1 Phase I (Other): 1 Phase I (FiH): 1 Other: 1

Oversight events:

6 serious breaches 14 temporary halts 1 unexpected event 1 corrective measure across 6 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 4 Triple negative breast cancer 2 Endometrial cancer metastatic 1 High grade B-cell lymphoma Burkitt-like lymphoma 1 Mantle cell lymphoma stage III 1 Rhabdomyosarcoma 1 B-cell unclassifiable lymphoma high grade 1 Follicular lymphoma stage IV 1 Mantle cell lymphoma stage II 1 Primary mediastinal large B-cell lymphoma 1 Follicular lymphoma stage III 1 Hormone receptor positive HER2 negative breast cancer 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 6 Unicancer 5 AstraZeneca AB 3 GPOH gGmbH 2 Kite Pharma Inc. 2 LYSARC 2 University Of Cologne 2 Acerta Pharma B.V. 1 Acrotech Biopharma Inc. 1 Amgen Inc. 1 Asoc Grupo Espanol De Investigacion En Sarcomas 1 Celgene Corp. 1

All trials

43 total

A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral… Pending

2024-511567-28-01 Phase II 1 country Kooperativni Lymfomova Skupina z.s.
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Phase III 7 countries Unicancer
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Phase III 5 countries Unicancer
HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 Phase III 4 countries Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and … Recruiting

2024-515245-42-00 Phase I (Other) 4 countries GPOH gGmbH
CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting

2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
Pembro-FLASH Recruiting

2022-501458-13-01 Phase II 1 country University Of Cologne
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 Phase III 15 countries AstraZeneca AB
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L… Recruiting

2022-501489-24-00 Phase III 7 countries Kite Pharma Inc.
A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting

2023-507803-76-00 Phase II/III 5 countries Acrotech Biopharma Inc.
HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting

2023-505377-32-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting

2023-505298-34-00 Phase II 1 country Unicancer
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 Phase III 2 countries University Of Saarland
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Phase III 8 countries GPOH gGmbH
Comparison of Cyclophosphamide and doxorubicin as a first line treatment in elderly patients with metastatic sarcoma Recruiting

2024-510653-10-00 Phase III 1 country Unicancer
Interest of peri operative CHemotherapy In patients with CINSARC highrisk localized Soft Tissue Sarcoma. Recruiting

2024-515384-62-00 Phase III 1 country Oncopole Claudius Regaud
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Phase I/II 16 countries The University Of Birmingham
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting

2022-501050-11-01 Phase II/III 14 countries Karolinska University Hospital
Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international r… Recruiting

2024-516196-32-00 Phase III 2 countries Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Phase II 5 countries Celgene Corp.
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Phase II 1 country University Of Cologne
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Phase III 9 countries Astrazeneca AB
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Phase III 15 countries Merck Sharp & Dohme LLC
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with inte… Ended

2024-513882-38-00 Phase II/III 1 country The Clatterbridge Cancer Centre NHS Foundation Trust

Showing 1–24 of 43 trials

← All drugs A–Z